RPE65

RPE65

RPE65 분자 정보

Molecule Name
Retinoid isomerohydrolase
분자 별명
BCO3, LCA2, RP20, mRPE65, p63, rd12, sRPE65
Drug Development Progress
임상 약물 수5
시판 약물 수1
최고 연구 개발 단계Approved
표적 별명
EC:5.3.3.22,Retinoid isomerohydrolase,All-trans-retinyl-palmitate hydrolase,Retinal pigment epithelium-specific 65 kDa protein,RPE65,RPE65, Retinoid Isomerohydrolase,Retinol Isomerase,Retinal Pigment Epithelium-Specific Protein 65kDa,EC 5.3.3.22,Retinoid Isomerohydrolase RPE65,Retinal Pigment Epithelium Specific Protein 65,EC 5.3.3.-,EC:3.1.1.64,Lutein Isomerase,Meso-Zeaxanthin Isomerase,BCO Family, Member 3,Retinitis Pigmentosa 20 (Autosomal Recessive),RBP-Binding Membrane Protein,EC 3.1.1.64,MRPE65,SRPE65,BCO3,LCA2,Rd12,RP20,P63

제품 문의

Asset Licensing Opportunity
Resources

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
Emixustat HydrochlorideACU-02; ACU-4429; ACU-4429 HClPhase 3 ClinicalAcucela Inc
Anetoderma; Geographic Atrophy; Stargardt Disease; Diabetic Retinopathy; Macular Degeneration
상세
LX-101LX-101Phase 3 ClinicalShanghai Langsheng Biological Technology Co Ltd
Retinal Dystrophies; Retinal Dysplasia; Retinal Degeneration
상세
HORA-RPE65 (Horama)HORA-RPE65Phase 2 ClinicalHorama Sa
Leber Congenital Amaurosis
상세
HG-004HG-004Phase 2 ClinicalHuiGene Therapeutics Ltd
Leber Congenital Amaurosis; Retinal Diseases
상세
FT-001(Frontera Therapeutics)FT-001; FT-001(Frontera Therapeutics)Phase 2 ClinicalFrontera Therapeutics Inc
Retinal Dysplasia
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
Voretigene neparvovec-rzyl2SPI046IKD; rAAV.hRPE65v2; AAV2-hRPE65v2; SPKRPE-65; rAAV2-CBSB-hRPE65; AAV2.RPE65ApprovedChildrens Hospital of PhiladelphiaLuxturnaUnited StatesRetinal DysplasiaSpark Therapeutics Inc2017-12-19
Vision Disorders; Retinal Dystrophies; Leber Congenital Amaurosis; Retinal Dysplasia
상세
Customer Reviews